fuckmekevinHonestly, marijuana should not be labeled as a schedule 1 drug. It can prevent the growth of certain tumors and that in and of itself completely contradicts the definition of a schedule 1 drug. Obviously, there are health concerns and abuse potential with smoking the substance but to ignore its medicinal properties is ludicrous. Kratom is another example of a substance that has recently come into legislative light. Yes, it has the potential for abuse but it also can be used to help patents suffering from CFS, Lyme disease and can also ween off heroin users. I have taken Kratom because I have debilitating joint pain from Lyme disease and I do not want to have to take synthetic pharmaceuticals based on a legality issue. I'm not hurting anyone, I'm an adult, leave me the fuck alone.
I'll reiterate what I said in a post above:
The reason you do not see a lot of "herbal" extracts used in medicines is due to the fact that they cannot be dosed appropriately/their efficacy is under question in a clinical setting. The FDA will NEVER let a drug, no matter the benefits, be approved if dosage levels, efficacy, and long-term safety results are not understood.
For example, there is a drug for a rare and fatal muscular dystrophy disease called Duchenne's Muscular Dystrophy (DMD) that has shown the ability to produce dystrophin (for some), therefore prolonging the lifespan of those affected (they live till 25). However, because of the trial design and the resulting data, it has not been approved despite pressure from politicians, patients, and patient-advocate groups.
The FDA has the responsibility to make sure no drug comes to the market that can do more harm than good, and if the FDA does not understand/approve of the dosage, efficacy, or safety profiles, it will not be approved. That is why you see marijuana, Kratom, and a whole host of other biologics and small molecules that are not approved for use in the USA.
Of course, with the marijuana side of things, companies are restricted by laws surrounding its usage for studies. That being said, you are seeing some cannabinoid-related drugs come through clinical trials, like GW Pharma's Epidiolex (CBD -based) or Insys's drug. Still, you have seen a host of others that have failed trials because they failed to meet their primary endpoints.